Senior Counsel John Litchfield was quoted in a Washington Post article, “You’ve come to expect your data is at risk when you shop. Don’t forget about when you’re at work,” about security breaches resulting in the exposure of employees’ personal data.
Litchfield said many employers are training workers to spot phishing emails by planting fakes, with some even running contests to see which corporate teams can avoid clicking on them the most and awarding the winning groups prizes such as extra paid time off. “I think the weakest link [for employee data] is these phishing scams, which are becoming much more sophisticated,” he said. “It’s harder and harder for people to recognize them.”
Litchfield said many employers are training workers to spot phishing emails by planting fakes, with some even running contests to see which corporate teams can avoid clicking on them the most and awarding the winning groups prizes such as extra paid time off. “I think the weakest link [for employee data] is these phishing scams, which are becoming much more sophisticated,” he said. “It’s harder and harder for people to recognize them.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”